Lv1
40 积分 2021-12-07 加入
The breast cancer drug market
3个月前
已完结
A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations
3个月前
已完结
The oncology market for antibody–drug conjugates
3个月前
已完结
[Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer]
4个月前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
5个月前
已关闭
德曲妥珠单抗临床管理路径及不良反应处理中国专家共识（2024版）
7个月前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
1年前
已关闭
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
1年前
已完结
[Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer]
1年前
已完结
[Consensus on clinical diagnosis and treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (2022 edition)]
1年前
已完结
皖公网安备34019202002308
